Skip to main content

AxCell s Becker Tapped to Run Cytogen as CEO Steps Down

For an updated version of this article, click here.


NEW YORK, Dec. 17 - Cytogen today said it has tapped AxCell chief Michael Becker to replace Joseph Reiser, who stepped down as president and CEO "for personal reasons" this afternoon.


Additionally, Lawrence Hoffman has quit as vice president and CFO, and Thu Dang, Cytogen's director of finance and 14-year veteran of the company, has been promoted to VP of finance.


It was not immediately clear whether Becker's ascension will affect AxCell, or if he will run both firms.


"As we look ahead to the next phase in Cytogen's evolution, I believe it is appropriate that Michael take on an expanded role as CEO," said Reiser, who will stay on as a board member.


Beside running AxCell, Becker was VP of business development and investor relations at Cytogen, where he has now been named to the board.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.